{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":20,"n_cols":5,"rows_kept":20,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910825396403321"]
[null,null,"Titolo",null,"Cytomegaloviruses . Volume I : from molecular pathogenesis to intervention / / edited by Matthias J. Reddehase ; with the assistance of Niels A.W. Lemmermann"]
[null,null,"Pubbl/distr/stampa",null,"Norfolk, England : , : Caister Academic Press, , [2013]"]
[{"$nulls":4},"©2013"]
[null,null,"ISBN",null,"1-912530-36-8"]
[{"$nulls":4},"1-908230-84-3"]
[null,null,"Descrizione fisica",null,"1 online resource (489 p.)"]
[null,null,"Disciplina",null,"576.64"]
[null,null,"Soggetti",null,"Cytomegaloviruses"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and indexes."]
[null,null,"Nota di contenuto",null,"Contents Volume I; Preface to the First Edition (2006); Preface; Abbreviations used in Vol I; Ch I.1: Comparative Genomics of Primate Cytomegaloviruses; Ch I.2: Molecular Evolution of Murine Cytomegalovirus Genomes; Ch I.3: Manipulating CMV Genomes by BAC Mutagenesis: Strategies and Applications; Ch I.4: Human Cytomegalovirus Metabolomics; Ch I.5: Cytomegalovirus-encoded miRNAs; Ch I.6: Cytomegalovirus Proteomics; Ch I.7: A Systems Pathway View of Cytomegalovirus Infection; Ch I.8: Virus Entry and Activation of Innate Defence; Ch I.9: Pre-Immediate Early Tegument Protein Functions"]
[{"$nulls":4},"Ch I.10: Major Immediate-Early Enhancer and Its Gene ProductsCh I.11: Multifaceted Regulation of Human Cytomegalovirus Gene Expression; Ch I.12: Intracellular Sorting and Trafficking of Cytomegalovirus Proteins during Permissive Infection; Ch I.13: Morphogenesis of the Cytomegalovirus Virion and Subviral Particles; Ch I.14: Exploitation of Host Cell Cycle Regulatory Pathways by HCMV; Ch I.15: Cell Death Pathways Controlled by Cytomegaloviruses; Ch I.16: Cytomegaloviruses and Interferons; Ch I.17: Cytomegalovirus Interstrain Variance in Cell Type Tropism"]
[{"$nulls":4},"Ch I.18: Molecular Basis of Cytomegalovirus Host Species SpecificityCh I.19: Epigenetic Regulation of Human Cytomegalovirus Gene Expression: Impact on Latency and Reactivation; Ch I.20: Transcription Associated with Human Cytomegalovirus Latency; Ch I.21: Myeloid Cell Recruitment and Function in Cytomegalovirus Dissemination and "]
[{"$nulls":4},"Immunity; Ch I.22: Immune Surveillance of Cytomegalovirus Latency and Reactivation in Murine Models: Link to 'Memory Inflation'; Ch I.23: Humanized Mouse Models of Cytomegalovirus Pathogenesis and Latency; Subject index; Open reading frame index"]
[{"$nulls":4},"Cluster of differentiation indexCMV strains index; Antiviral drugs index; Frequently discussed molecules"]
[null,null,null,"Sommario/riassunto","Human Cytomegalovirus (CMV) - a member of the herpesvirus family - is an underrated health risk. A low public awareness results from the relatively mild symptoms it causes in otherwise healthy people whose immune systems are intact, with primary infection usually going unnoticed. During pregnancy, however, transmission from the mother to the fetus is currently the most frequent viral cause of birth defects with lifelong neurological sequelae, sensorineural hearing loss in particular. People at risk also include the growing number of immune compromised patients requiring either a solid organ gr"]